Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters

被引:59
作者
Dhar, Debanjan [1 ]
Spencer, Jacqueline F. [1 ]
Toth, Karoly [1 ]
Wold, William S. M. [1 ]
机构
[1] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA
基金
美国国家卫生研究院;
关键词
HERPES-SIMPLEX-VIRUS; GLIOMA VIROTHERAPY; GENE-TRANSFER; ANIMAL-MODEL; CELL-LYSIS; THERAPY; CANCER; REPLICATION; RESPONSES; TOXICITY;
D O I
10.1128/JVI.02127-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Immune responses against adenovirus (Ad) vectors pose a possible concern for the outcome of treatment efficacy. To address the role of preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of vector as well as tumor-to-tissue spread of the vector, we employed the Syrian hamster model. These animals are immunocompetent, and their tumors and tissues are permissive for replication of Ad type 5 (Ad5). We used the adenovirus death protein-overexpressing Ad5-based vector INGN 007. Subcutaneous tumors were established in groups of hamsters that were or were not immunized with Ad5. Half of the hamsters in these groups were immunosuppressed with cyclophosphamide. For all groups, tumors injected with INGN 007 grew significantly more slowly than those injected with buffer. Under immunocompetent conditions, there was no significant effect of preexisting immunity on vector antitumor efficacy. Soon after the tumors in naive animals were injected with vector, the hamsters developed neutralizing antibody (NAb) and the difference in NAb titers between the naive and immunized groups diminished. Under immunosuppressed conditions, preexisting NAb did significantly reduce vector efficacy. Thus, NAb do reduce vector efficacy to some extent, but immunosuppression is required to observe the effect. Regarding vector toxicity, there was spillover of vector from the tumor to the liver and lungs in naive immunocompetent hamsters, and this was nearly eliminated in the immunized hamsters. Thus, preexisting immunity to Ad5 does not affect INGN 007 antitumor efficacy following intratumoral injection, but immunity prevents vector spillover from the tumor to the liver and lungs.
引用
收藏
页码:2130 / 2139
页数:10
相关论文
共 42 条
[1]  
[Anonymous], ADENOVIRUS METHODS P
[2]   Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination [J].
Bramson, JL ;
Hitt, M ;
Gauldie, J ;
Graham, FL .
GENE THERAPY, 1997, 4 (10) :1069-1076
[3]   Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded [J].
Cattaneo, Roberto ;
Miest, Tanner ;
Shashkova, Elena V. ;
Barry, Michael A. .
NATURE REVIEWS MICROBIOLOGY, 2008, 6 (07) :529-540
[4]   Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy [J].
Chen, Y ;
Yu, DC ;
Charlton, D ;
Henderson, DR .
HUMAN GENE THERAPY, 2000, 11 (11) :1553-1567
[5]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[6]  
Condit R.C., 2001, Fields Virology, V4, P19
[7]  
Crompton AM, 2007, CURR CANCER DRUG TAR, V7, P133
[8]   Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy [J].
Delman, KA ;
Bennett, JJ ;
Zager, JS ;
Burt, BM ;
McAuliffe, PF ;
Petrowsky, H ;
Kooby, DA ;
Hawkins, WG ;
Horsburgh, BC ;
Johnson, P ;
Fong, Y .
HUMAN GENE THERAPY, 2000, 11 (18) :2465-2472
[9]   Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus [J].
Doronin, K ;
Toth, K ;
Kuppuswamy, M ;
Krajcsi, P ;
Tollefson, AE ;
Wold, WSM .
VIROLOGY, 2003, 305 (02) :378-387
[10]  
Ebert O, 2003, CANCER RES, V63, P3605